🟢 Edesa Biotech is trading 6.38% up in pre-market amid broader biotech strength

Edesa Biotech is trading at $3.00, up +6.38% in pre-market, with broader biotech strength the likeliest context, though no direct cause is established.

• Biotech ETF XBI was up 3.64% pre-market.
• No new company-specific announcement explaining the October 21 pre-market move was identified; the latest located catalyst was October 15 FDA clearance to expand the EB06 vitiligo Phase 2 study into U.S. sites.
• Edesa Biotech also had an unexplained after-hours move on October 20.